Crossmark

Health-related quality of life among anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients treated with first- and next-generation ALK tyrosine kinase inhibitors (TKIs): a systematic review and meta-analysis

Crossref DOI link: https://doi.org/10.1007/s11136-025-04088-6

Published Online: 2025-11-28

Published Print: 2025-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Huang, Yan

Chu, Qian

Wang, Jiejun

Zhang, Li
Funding

Funding for this research was provided by:

Takeda (China) International Trading Co., Ltd (Takeda (China) International Trading Co., Ltd)
License Information

Text and Data Mining valid from 2025-11-01

Version of Record valid from 2025-11-28
More Information

Article History

Received: 8 April 2025

Accepted: 29 September 2025

First Online: 28 November 2025

Declarations

:

: Li Zhang: Member of advisory council/committees for Takeda; Honoraria of Takeda. Yan Huang: Honoraria of Takeda. Qian Chu: Honoraria of Takeda. Jiejun Wang has no conflict of interest to disclose.

Document is current

Any future updates will be listed below